{"log_id": 8126200751031513268, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0.019738, "average": 0.859507, "min": 0.719013}, "location": {"width": 92, "top": 144, "height": 20, "left": 760}, "words": " czr-hk/CN"}, {"probability": {"variance": 0.004604, "average": 0.979636, "min": 0.666043}, "location": {"width": 887, "top": 201, "height": 78, "left": 172}, "words": "尿剂、钙通道阻滞剂、a-或β-受体阻滞剂和中枢作用药物。病人随访时间长达4.6年(平均"}, {"probability": {"variance": 4e-06, "average": 0.998545, "min": 0.990944}, "location": {"width": 827, "top": 285, "height": 76, "left": 216}, "words": "研究首要终点是血清肌酐浓度的加倍、终末期肾病(需透析或肾移植)或死亡的综合终点"}, {"probability": {"variance": 4e-06, "average": 0.998249, "min": 0.994388}, "location": {"width": 74, "top": 292, "height": 23, "left": 175}, "words": "3.4年)"}, {"probability": {"variance": 1.2e-05, "average": 0.997161, "min": 0.98523}, "location": {"width": 889, "top": 327, "height": 77, "left": 176}, "words": "研究结果表明,与安慰剂组(359例)相比,氯沙坦组(327例)降低患者首要综合终点的危"}, {"probability": {"variance": 4.9e-05, "average": 0.996975, "min": 0.956092}, "location": {"width": 889, "top": 368, "height": 78, "left": 178}, "words": "险达16.1%(p=0.022)。在下列单独和综合的首要终点方面,氯沙坦组同样显示出危险性的显"}, {"probability": {"variance": 0.000261, "average": 0.9956, "min": 0.887571}, "location": {"width": 885, "top": 410, "height": 77, "left": 181}, "words": "著下降:血清肌酐浓度加倍的危险下降25.3%(p=0.006);终末期肾病的危险下降28.6%"}, {"probability": {"variance": 3e-05, "average": 0.997047, "min": 0.974005}, "location": {"width": 884, "top": 451, "height": 78, "left": 186}, "words": "(=0.002);终末期肾病或死亡的危险下降19.9%(p=0.009);血清肌酐浓度加倍或终末期肾"}, {"probability": {"variance": 0.000371, "average": 0.994649, "min": 0.872317}, "location": {"width": 829, "top": 496, "height": 74, "left": 182}, "words": "病的危险下降21.0%(p=0.010).两个治疗组中,所有原因引起的死亡率没有显著差异"}, {"probability": {"variance": 2e-06, "average": 0.998901, "min": 0.994071}, "location": {"width": 847, "top": 576, "height": 72, "left": 228}, "words": "研究的次要终点是蛋白尿的变化、肾脏疾病进展速率、心血管疾病的患病率和死亡率的综"}, {"probability": {"variance": 1.2e-05, "average": 0.997829, "min": 0.987759}, "location": {"width": 886, "top": 617, "height": 75, "left": 190}, "words": "合终点(包括心衰、心肌梗塞、血管重建和中风引起的住院,不稳定型心绞痛引起的住院或心"}, {"probability": {"variance": 0.012662, "average": 0.965668, "min": 0.36698}, "location": {"width": 889, "top": 658, "height": 75, "left": 190}, "words": "血管死亡)。结果显示,氯沙坦组患者的蛋白尿水平平均下降34.3%(p0.001)。在长期的研"}, {"probability": {"variance": 3e-06, "average": 0.999021, "min": 0.990958}, "location": {"width": 890, "top": 699, "height": 75, "left": 191}, "words": "究中,采用血清肌酐浓度的倒数进行评估,氯沙坦组降低肾功能减退的速率达13.9%"}, {"probability": {"variance": 0.000207, "average": 0.994291, "min": 0.918287}, "location": {"width": 854, "top": 742, "height": 71, "left": 229}, "words": "=.003)(降低肾功能减退速率的中位数达18.5%,p=0.01)。在心血管疾病患病率和死亡"}, {"probability": {"variance": 2.1e-05, "average": 0.997779, "min": 0.972057}, "location": {"width": 880, "top": 783, "height": 74, "left": 196}, "words": "率的综合终点方面,尽管本研究没有足够的效能检验这一综合终点,但是氯沙坦组(247例)"}, {"probability": {"variance": 2.4e-05, "average": 0.996419, "min": 0.985198}, "location": {"width": 346, "top": 851, "height": 46, "left": 199}, "words": "和安慰剂组(268例)没有显著差别"}, {"probability": {"variance": 8e-06, "average": 0.998334, "min": 0.987012}, "location": {"width": 846, "top": 865, "height": 71, "left": 243}, "words": "在这个研究中,氯沙坦可以很好耐受。由于不良事件而中止研究的发生率在两组是相似"}, {"probability": {"variance": 0, "average": 0.999332, "min": 0.999332}, "location": {"width": 25, "top": 952, "height": 25, "left": 204}, "words": "的"}, {"probability": {"variance": 8.2e-05, "average": 0.994756, "min": 0.974832}, "location": {"width": 110, "top": 990, "height": 26, "left": 206}, "words": "[药理毒理]"}, {"probability": {"variance": 0.001898, "average": 0.989748, "min": 0.736505}, "location": {"width": 844, "top": 1029, "height": 72, "left": 250}, "words": "血管紧张素II是肾素-血管紧张素系统的主要活性物质,为强效的血管收缩剂,在高血"}, {"probability": {"variance": 1e-06, "average": 0.998566, "min": 0.997179}, "location": {"width": 89, "top": 1031, "height": 27, "left": 207}, "words": "作用机制"}, {"probability": {"variance": 0.002888, "average": 0.984321, "min": 0.678444}, "location": {"width": 888, "top": 1071, "height": 73, "left": 209}, "words": "压的病理生理过程中起主要作用。血管紧张素II在多种组织内与AT1受体结合(如血管平滑"}, {"probability": {"variance": 5.4e-05, "average": 0.997766, "min": 0.952915}, "location": {"width": 868, "top": 1113, "height": 72, "left": 210}, "words": "肌、肾上腺、肾脏和心脏),产生包括血管收缩和醛固酮释放在内的多种重要的生物学效应"}, {"probability": {"variance": 0.000484, "average": 0.991578, "min": 0.909085}, "location": {"width": 886, "top": 1154, "height": 72, "left": 213}, "words": "同时,它还能够刺激平滑肌细胞增殖。已证实另一种血管紧张素II受体亚型为AT2,但它对"}, {"probability": {"variance": 1.4e-05, "average": 0.995585, "min": 0.991876}, "location": {"width": 90, "top": 1188, "height": 48, "left": 998}, "words": "药有"}, {"probability": {"variance": 1.9e-05, "average": 0.9984, "min": 0.981047}, "location": {"width": 372, "top": 1220, "height": 47, "left": 214}, "words": "于心血管系统功能稳态的作用尚不明确"}, {"probability": {"variance": 0.000208, "average": 0.994259, "min": 0.914881}, "location": {"width": 847, "top": 1235, "height": 74, "left": 259}, "words": "氯沙坦为合成的、强效口服活性药物。结合试验和药理学生物检测证明它能与AT1体选"}, {"probability": {"variance": 0.000955, "average": 0.98768, "min": 0.822785}, "location": {"width": 888, "top": 1277, "height": 74, "left": 217}, "words": "择性结合。体内外研究表明:氯沙坦及其具有药理活性的羧酸代谢产物(E-3174可以阻断任何"}, {"probability": {"variance": 0.000647, "average": 0.992575, "min": 0.844286}, "location": {"width": 884, "top": 1320, "height": 72, "left": 219}, "words": "来源或任何途径合成的血管紧张素II所产生的相应的生理作用。与其他肽类的血管紧张素I"}, {"probability": {"variance": 0.000742, "average": 0.990492, "min": 0.892732}, "location": {"width": 309, "top": 1391, "height": 42, "left": 221}, "words": "拮抗剂相比,氯沙坦无激动作用"}, {"probability": {"variance": 0, "average": 0.658606, "min": 0.658606}, "location": {"width": 213, "top": 1426, "height": 133, "left": 963}, "words": " FPHARHACEUTICALC"}, {"probability": {"variance": 0.000755, "average": 0.983244, "min": 0.928733}, "location": {"width": 123, "top": 1498, "height": 39, "left": 989}, "words": "杭州默沙东"}, {"probability": {"variance": 0.063536, "average": 0.811647, "min": 0.361125}, "location": {"width": 217, "top": 1541, "height": 42, "left": 942}, "words": "制有限公司8"}], "language": 3}